| Popis: |
In early April 2012, Michelle Dipp, MD, Ph.D, CEO and co-founder of OvaScience, had just received a buyout offer from PG Ventures, a private equity firm interested in acquiring the innovative fertility treatments company. The company's first promising fertility treatment, AUGMENT (Autologous Germ-line Mitochondrial Energy Transfer), had the potential to improve egg quality, increase the success of IVF cycles, and decrease the incidence of multiple births (i.e., twins, triplets). OvaScience had been in operation since 2011, and AUGMENT had not yet reached the market. Dipp and her partners had high hopes for the success of AUGMENT and the impact the underlying technology could have on millions of infertility cases around the world. How fast might Dipp and her team grow OvaScience? Would they have the resources? Dipp considered the best way to build out OvaScience's business model and whether AUGMENT's potential outweighed the PG Ventures offer. |
